CEL-SCI Corp.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About CEL-SCI Corp.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
/ 
Frequently asked questions
To buy CEL-SCI Corp. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for CEL-SCI Corp. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for CEL-SCI Corp. is CVM:xase. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
CEL-SCI Corp. has its primary listing on NYSE American. You can trade CEL-SCI Corp. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, CEL-SCI Corp. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include CEL-SCI Corp. as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like CEL-SCI Corp..